When was Shennon Biotechnologies founded?

Shennon Biotechnologies was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Shennon Biotechnologies located?

Shennon Biotechnologies is headquartered in San Francisco, United States.

How many employees does Shennon Biotechnologies have?

As of Sep 30, 2026, the latest employee count at Shennon Biotechnologies is 19.

Is Shennon Biotechnologies a funded company?

Shennon Biotechnologies is a funded company, having raised a total of $25M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 13, 2023.

When was the latest funding round of Shennon Biotechnologies?

Shennon Biotechnologies' latest funding was a $***** Seed round on Sep 14, 2026, with participation from 8 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.27B in funding in 2026 to date.

Where does Shennon Biotechnologies rank among its competitors?

Shennon Biotechnologies ranks 452nd amongst 3665 active competitors, of which 1204 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Shennon Biotechnologies, which secured $12M in Sep, 2026.

Who are the top competitors of Shennon Biotechnologies?

Shennon Biotechnologies' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Shennon Biotechnologies secured the most recent funding round in September, 2026.

Shennon Biotechnologies - 2026 Company Profile, Funding & Competitors

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 14, 2026	2810501	Seed	1315320	5491030	1929204	9868016
Mar 13, 2023	4024233	Seed	7209869	5902620	DCVC	Foundation Capital & 1 more

Shennon Biotechnologies' employee count trend

Shennon Biotechnologies has 19 employees as of Sep 26. Here is Shennon Biotechnologies's employee count trend over the years:

Employee count trend for Shennon Biotechnologies

Uncover Shennon Biotechnologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Shennon Biotechnologies include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Shennon Biotechnologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
452nd	Shennon Biotechnologies 2021, San Francisco (United States), Seed	Developer of immune cell therapies against solid tumors and autoimmune disease	$25M	Foundation Capital, DCVC & 7 others	54/100